GlassScriptPhysician profile
Chaula S Kharode
NPI 1104864263
$1,624.74
in general payments reported to CMS, 2019-2025
18 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $245 · 2022: $412 · 2023: $228 · 2024: $298 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $186.13 | 2023-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $181.30 | 2022 | |
| Ironshore Pharmaceuticals INC. | $168.13 | 2020-2024 | |
| Ucb, INC. | $163.95 | 2019-2023 | Briviact |
| Boston Scientific Corporation | $120.10 | 2020 | |
| Supernus Pharmaceuticals, INC. | $119.22 | 2024-2025 | Qelbree |
| Biomarin Pharmaceutical INC. | $118.64 | 2023 | Brineura |
| Biogen, INC. | $112.30 | 2019 | |
| Impel Pharmaceuticals INC. | $97.65 | 2022 | |
| Lundbeck LLC | $91.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $54.48 | 2024-2025 | Ultomiris |
| Neos Therapeutics, LP | $40.71 | 2024 | Adzenys Xr-Odt |
| Grifols USA, LLC | $36.76 | 2025 | Gamunex-C |
| Evofem Biosciences, INC. | $33.54 | 2024 | |
| Abbvie INC. | $31.51 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.38 | 2023 | |
| Sunovion Pharmaceuticals INC. | $23.76 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.78 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaula Kharode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.